vs
Side-by-side financial comparison of Anika Therapeutics, Inc. (ANIK) and STEM, INC. (STEM). Click either name above to swap in a different company.
STEM, INC. is the larger business by last-quarter revenue ($47.1M vs $29.6M, roughly 1.6× Anika Therapeutics, Inc.). On growth, Anika Therapeutics, Inc. posted the faster year-over-year revenue change (13.2% vs -15.6%). Over the past eight quarters, STEM, INC.'s revenue compounded faster (36.1% CAGR vs -1.8%).
StemCells, Inc. is a public biopharmaceutical company headquartered in Newark, California, that is developing purified human neural stem cells (HuCNS-SCs) in the hopes of treating central nervous system disorders and paralysis. StemCells' HuCNS-SCs have the ability to differentiate into the three main types of cells found in the central nervous system: neurons, astrocytes and oligodendrocytes.
ANIK vs STEM — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $29.6M | $47.1M |
| Net Profit | — | $-16.0M |
| Gross Margin | 64.2% | 48.9% |
| Operating Margin | — | -17.7% |
| Net Margin | — | -33.9% |
| Revenue YoY | 13.2% | -15.6% |
| Net Profit YoY | — | 68.8% |
| EPS (diluted) | $0.27 | $-4.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $29.6M | — | ||
| Q4 25 | $30.6M | $47.1M | ||
| Q3 25 | $27.8M | $38.2M | ||
| Q2 25 | $28.2M | $38.4M | ||
| Q1 25 | $26.2M | $32.5M | ||
| Q4 24 | $30.6M | $55.8M | ||
| Q3 24 | $29.6M | $29.3M | ||
| Q2 24 | $30.7M | $34.0M |
| Q1 26 | — | — | ||
| Q4 25 | $292.0K | $-16.0M | ||
| Q3 25 | $-2.3M | $-23.8M | ||
| Q2 25 | $-4.0M | $202.5M | ||
| Q1 25 | $-4.9M | $-25.0M | ||
| Q4 24 | $-21.9M | $-51.1M | ||
| Q3 24 | $-29.9M | $-148.3M | ||
| Q2 24 | $-88.0K | $-582.3M |
| Q1 26 | 64.2% | — | ||
| Q4 25 | 62.6% | 48.9% | ||
| Q3 25 | 56.0% | 35.5% | ||
| Q2 25 | 50.9% | 33.4% | ||
| Q1 25 | 56.1% | 32.4% | ||
| Q4 24 | 56.0% | -4.4% | ||
| Q3 24 | 65.7% | 21.2% | ||
| Q2 24 | 66.7% | 27.6% |
| Q1 26 | — | — | ||
| Q4 25 | 2.1% | -17.7% | ||
| Q3 25 | -11.6% | -33.6% | ||
| Q2 25 | -14.8% | -34.8% | ||
| Q1 25 | -16.4% | -65.0% | ||
| Q4 24 | -2.3% | -84.4% | ||
| Q3 24 | -0.3% | -493.2% | ||
| Q2 24 | -5.9% | -1705.5% |
| Q1 26 | — | — | ||
| Q4 25 | 1.0% | -33.9% | ||
| Q3 25 | -8.4% | -62.2% | ||
| Q2 25 | -14.1% | 527.8% | ||
| Q1 25 | -18.6% | -76.9% | ||
| Q4 24 | -71.4% | -91.6% | ||
| Q3 24 | -101.2% | -506.3% | ||
| Q2 24 | -0.3% | -1712.6% |
| Q1 26 | $0.27 | — | ||
| Q4 25 | $0.02 | $-4.40 | ||
| Q3 25 | $-0.16 | $-2.84 | ||
| Q2 25 | $-0.28 | $-1.79 | ||
| Q1 25 | $-0.34 | $-0.15 | ||
| Q4 24 | $-1.49 | $-15.29 | ||
| Q3 24 | $-2.03 | $-18.24 | ||
| Q2 24 | $0.00 | $-71.81 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $41.0M | $48.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $133.9M | $-249.4M |
| Total Assets | $179.4M | $308.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $41.0M | — | ||
| Q4 25 | $81.2M | $48.9M | ||
| Q3 25 | $80.2M | $43.1M | ||
| Q2 25 | $77.1M | $40.8M | ||
| Q1 25 | $75.4M | $58.6M | ||
| Q4 24 | $79.2M | $56.3M | ||
| Q3 24 | $90.7M | $75.4M | ||
| Q2 24 | $96.6M | $89.6M |
| Q1 26 | $133.9M | — | ||
| Q4 25 | $143.5M | $-249.4M | ||
| Q3 25 | $146.8M | $-235.7M | ||
| Q2 25 | $147.7M | $-214.1M | ||
| Q1 25 | $148.4M | $-417.5M | ||
| Q4 24 | $154.0M | $-398.4M | ||
| Q3 24 | $179.9M | $-344.1M | ||
| Q2 24 | $210.3M | $-203.2M |
| Q1 26 | $179.4M | — | ||
| Q4 25 | $190.3M | $308.9M | ||
| Q3 25 | $189.4M | $362.6M | ||
| Q2 25 | $187.7M | $379.2M | ||
| Q1 25 | $190.6M | $405.1M | ||
| Q4 24 | $202.7M | $437.4M | ||
| Q3 24 | $231.4M | $537.8M | ||
| Q2 24 | $262.7M | $691.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $8.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $4.6M | $8.2M | ||
| Q3 25 | $6.9M | $11.4M | ||
| Q2 25 | $-189.0K | $-21.3M | ||
| Q1 25 | $-130.0K | $8.5M | ||
| Q4 24 | $1.6M | $-14.7M | ||
| Q3 24 | $5.0M | $-9.4M | ||
| Q2 24 | $-1.1M | $-11.9M |
| Q1 26 | — | — | ||
| Q4 25 | $4.0M | — | ||
| Q3 25 | $5.0M | — | ||
| Q2 25 | $-1.7M | — | ||
| Q1 25 | $-3.0M | — | ||
| Q4 24 | $275.0K | — | ||
| Q3 24 | $3.8M | — | ||
| Q2 24 | $-4.5M | — |
| Q1 26 | — | — | ||
| Q4 25 | 13.0% | — | ||
| Q3 25 | 17.9% | — | ||
| Q2 25 | -5.9% | — | ||
| Q1 25 | -11.3% | — | ||
| Q4 24 | 0.9% | — | ||
| Q3 24 | 12.9% | — | ||
| Q2 24 | -14.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | 2.1% | — | ||
| Q3 25 | 6.8% | — | ||
| Q2 25 | 5.2% | — | ||
| Q1 25 | 10.8% | — | ||
| Q4 24 | 4.3% | — | ||
| Q3 24 | 4.1% | — | ||
| Q2 24 | 11.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | 15.88× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.11× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
